Advertisement

Supportive Care in Cancer

, Volume 26, Issue 7, pp 2103–2111 | Cite as

Effects of Shengmai injection add-on therapy to chemotherapy in patients with non-small cell lung cancer: a meta-analysis

  • Baoqi Duan
  • Jinsong Xie
  • Qinglin Rui
  • Wenxi Zhang
  • Zhaoqing Xi
Review Article

Abstract

Purpose

Shengmai injection (SMI) has shown promising outcomes in the management of non-small cell lung cancer (NSCLC). This meta-analysis aimed to investigate the add-on effects of SMI to chemotherapy in NSCLC patients.

Methods

A comprehensive literature search was performed in the Cochrane Library, PubMed, Embase, CNKI, VIP, and Wanfang up to December 2017. Only randomized controlled trials (RCTs) evaluating SMI in combination with chemotherapy versus chemotherapy alone in NSCLC patients were eligible. The outcome measures were quality of life, chemotherapy-induced grade 3/4 myelosuppression or gastrointestinal reactions, and objective tumor response (equals complete response plus partial response). Pooled risk ratio (RR) with 95% confidence interval (CI) was used to evaluate dichotomous and continuous outcome, respectively.

Results

A total of 15 RCTs were included and analyzed. Meta-analysis showed that SMI combined with chemotherapy was associated with a significant improvement in Karnofsky Performance Status (RR 2.36; 95% CI 1.50–3.96) compared with the chemotherapy alone. Moreover, adjunctive treatment with SMI significantly reduced grade 3/4 myelosuppression (RR 0.61; 95% CI 0.46–0.81) and gastrointestinal reactions (RR 0.64; 95% CI 0.46–0.90). However, there was no significant difference in objective tumor response (RR 1.17; 95% CI 0.99–1.37) between two groups.

Conclusions

SMI add-on therapy appeared to be more effective in improving quality of life and reducing chemotherapy-induced adverse effects. However, more well-designed RCTs are warranted to confirm the findings of this meta-analysis because of the suboptimal methodological quality of the included trials.

Keywords

Shengmai injection Non-small cell lung cancer Side effects Quality of life Meta-analysis 

Notes

Funding

This work was supported by the National Natural Science Foundation of China (Foundation item number: 81673933).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

Ethical approval was not necessary due to this meta-analysis adopted the study-level data. This article adopted the study-level data.

Supplementary material

520_2018_4167_Fig6_ESM.gif (7 kb)
Supplemental Figure S1

Funnel Plots based on improvement in Karnofsky Performance Status (A) and objective tumor response (B). (GIF 7 kb)

520_2018_4167_MOESM1_ESM.tif (200 kb)
High Resolution Image (TIFF 200 kb)

References

  1. 1.
    Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5–29CrossRefPubMedGoogle Scholar
  2. 2.
    Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008) Non-small cell lung cancer: epidemiology risk factors, treatment, and survivorship. Mayo Clin Proc 83(5):584–594CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL, Paz-Ares L (2017) Lung cancer: current therapies and new targeted treatments. Lancet 389(10066):299–311CrossRefPubMedGoogle Scholar
  4. 4.
    Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D’Amico TA, DeCamp MM, Dilling TJ, Dobelbower M, Doebele RC, Govindan R, Gubens MA, Hennon M, Horn L, Komaki R, Lackner RP, Lanuti M, Leal TA, Leisch LJ, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M (2017) Non-small cell lung Cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 15(4):504–535CrossRefGoogle Scholar
  5. 5.
    Shojaee S, Nana-Sinkam P (2017) Recent advances in the management of non-small cell lung cancer. F1000Res 6:2110.  https://doi.org/10.12688/f1000research.11471.1 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Jiao L, Dong C, Liu J, Chen Z, Zhang L, Xu J, Shen X, Che J, Yang Y, Huang H, Li H, Sun J, Jiang Y, Mao Z, Chen P, Gong Y, Jin X, Xu L (2017) Effects of Chinese medicine as adjunct medication for adjuvant chemotherapy treatments of non-small cell lung cancer patients. Sci Rep 7:46524CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Han Y, Wang H, Xu W, Cao B, Han L, Jia L, Xu Y, Zhang Q, Wang X, Zhang G, Yu M, Yang G (2016) Chinese herbal medicine as maintenance therapy for improving the quality of life for advanced non-small cell lung cancer patients. Complement Ther Med 24:81–89CrossRefPubMedGoogle Scholar
  8. 8.
    Jiang Y, Liu LS, Shen LP, Han ZF, Jian H, Liu JX, Xu L, Li HG, Tian JH, Mao ZJ (2016) Traditional Chinese medicine treatment as maintenance therapy in advanced non-small-cell lung cancer: a randomized controlled trial. Complement Ther Med 24:55–62CrossRefPubMedGoogle Scholar
  9. 9.
    Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(4):264–269 W264CrossRefPubMedGoogle Scholar
  10. 10.
    Schag CC, Heinrich RL, Ganz PA (1984) Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 2(3):187–193CrossRefPubMedGoogle Scholar
  11. 11.
    Ramalingam S, Belani CP (2002) Doublet chemotherapy for advanced non-small cell lung cancer. Clin Lung Cancer 4(1):13PubMedGoogle Scholar
  12. 12.
    Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1):207–214CrossRefPubMedGoogle Scholar
  13. 13.
    Zhou GF, Li AJ (2003) Shengmai injection treatment for chemotherapy-reduced adverse reaction in non-small cell lung cancer 30 cases of patients. CJITWM 23(3):231–232Google Scholar
  14. 14.
    Li GX (2005) Clinical observation of Shengmai injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer. JETCM 14(3):233–234Google Scholar
  15. 15.
    Wang R, Wang ZX, Wang QC (2006) Shengmai injection combined with gemcitabine plus cisplatin cure advanced NSCLC. Suzhou Univ J Med Sci 26(4):631–633Google Scholar
  16. 16.
    Liang CW (2007) Clinical study on the treatment of advanced NSCLC with Shengmai injection combined with chemotherapy. J Anhui TCM Coll 26(3):15–18Google Scholar
  17. 17.
    Yao JT, Wang YZ, Zhang YJ, Wu HM, Zhao Z (2007) Clinical observation of Shengmai injection combined chemotherapy in advanced lung cancer. J Mod Oncol 15(8):1119–1120Google Scholar
  18. 18.
    Zhang QH (2008) Clinical observation of adjunctive treatment with Shengmai injection in non small cell lung cancer. Mod J Integr Tradit Chin West Med 17(24):3827–3828Google Scholar
  19. 19.
    Sun DB, Han Y (2009) The VEGF levels after pulse-activating ingection combined with interventional chemotherapy for non-small cell lung cancer. J Xinjiang Med Univ 32(9):1282–1284Google Scholar
  20. 20.
    Chen QS, Chen Y, Yang ZJ, Liu JB, Pei RQ (2011) The effect on quality of life to advanced stage non-small cell lung cancer patient treated with Shengmai injection combined chemotherapy. China J Chin Med 26(1):13–15Google Scholar
  21. 21.
    Lu XA (2011) Effect of Shengmai injection combined with chemotherapy on the quality of life and immune function in patients with advanced non-small cell lung cancer. Shaanxi J Tradit Chin Med 32(4):389–391Google Scholar
  22. 22.
    Bao YH (2011) Effect of Shengmai injection on the quality of life of patients with advanced non-small cell lung cancer receiving chemotherapy. Chin J Clin Res 24(11):1037–1038Google Scholar
  23. 23.
    Yang ZJ, Deng CM, Qiu YH, Mo BS (2012) Shengmai injection combined with NP regimen in the treatment of 30 cases of advanced non-small cell lung cancer. World Health Dig Med Periodieal 9(26):124–125Google Scholar
  24. 24.
    Wu Q, He X (2012) Clinical observation of Shengmai injection combined with chemotherapy in the treatment of middle to advanced lung cancer. Chin J Tradit Med Sci Technol 19(1):71–72Google Scholar
  25. 25.
    Wang DJ (2012) Efficacy of Shengmai injection combined with TP regimen in the treatment of advanced non-small cell lung cancer. Jilin Med J 33(11):2315–2316Google Scholar
  26. 26.
    Liu JY, Liu BY, Liu Y (2014) Clinical efficacy of Shengmai injection combined with gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer. China J Pharm Econ 9(11):211–212Google Scholar
  27. 27.
    Zhang CM (2016) Effect of Shengmai injection combined with chemotherapy in the treatment of patients with advanced non-small cell lung cancer. Chin Prim Health Care 30(7):92–93Google Scholar
  28. 28.
    Mannion E, Gilmartin JJ, Donnellan P, Keane M, Waldron D (2014) Effect of chemotherapy on quality of life in patients with non-small cell lung cancer. Support Care Cancer 22(5):1417–1428CrossRefPubMedGoogle Scholar
  29. 29.
    Li Q, Liu H (2005) Pharmacological action and clinical application of Shengmai injection. Med Recapitulate 11(10):950–952Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of EmergencyJiangsu Province Hospital of TCM, Affiliated Hospital of Nanjing University of Chinese MedicineNanjingChina
  2. 2.Department of Clinical LaboratorJiangsu Province Infectious Disease HospitalNanjingChina
  3. 3.Department of OncologyJiangsu Province Hospital of TCM, Affiliated Hospital of Nanjing University of Chinese MedicineNanjingChina
  4. 4.Medical expert center of Jiangsu Province Hospital of TCM, Affiliated Hospital of Nanjing University of Chinese MedicineNanjingChina

Personalised recommendations